Categories
Change Password!
Reset Password!
Finerenone reduces the risk of heart failure occurrence and hospitalization, particularly in patients with CKD and diabetes, but does not demonstrate a clear impact on overall mortality.
Heart failure (HF) remains a major global health burden, and the search for therapies that effectively slow disease progression continues to intensify. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, is increasingly recognized for its cardiovascular and renal benefits in chronic kidney disease (CKD) and diabetes. As clinical interest grows, the need to clarify its role in preventing HF deterioration becomes more urgent.
The present study explored finerenone's preliminary effectiveness and safety in reducing HF occurrence, worsening, and related clinical outcomes across randomized controlled trials (RCTs) involving adults with HF, diabetes, or CKD who received finerenone therapy. Eligible trials were selected according to PRISMA guidelines, and data on HF outcomes, hospitalization risk, cardiovascular mortality, and all-cause mortality were extracted for pooled analysis. Risk of bias was assessed using the Cochrane Handbook, and heterogeneity was addressed through standard statistical techniques.
In this systematic review and meta-analysis, 6 RCTs with 21,295 participants were included.
Finerenone emerged as a beneficial therapy that reduced HF progression and hospitalization risk, particularly in patients with CKD or diabetes who were vulnerable to worsening cardiovascular outcomes. While it did not improve overall mortality metrics, its favorable safety profile and measurable effects on HF events highlighted its potential as a valuable adjunct to current treatment regimens.
Frontiers in Pharmacology
A systematic review and meta-analysis on the efficacy and safety of finerenone in the progression of heart failure
Shengtian Peng et al.
Comments (0)